Ventoxen 100 mg (Venetoclax) Tablets

Ventoxen 100 mg contains Venetoclax, a targeted anticancer medicine that belongs to the BCL-2 inhibitor class. It is used as part of specific treatment regimens for certain blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and selected cases of acute myeloid leukemia (AML).

Key Uses

• Used in the treatment of chronic lymphocytic leukemia (CLL) in appropriate patients.
• Used for small lymphocytic lymphoma (SLL) according to the prescribed treatment regimen.
• Used in combination with other medicines for certain adults with newly diagnosed acute myeloid leukemia (AML) who meet treatment criteria.
• May be incorporated into combination treatment plans depending on the cancer type, previous therapy, patient characteristics, and clinical assessment.

Therapeutic Effect

Venetoclax works by selectively inhibiting the B-cell lymphoma 2 (BCL-2) protein, which helps certain cancer cells survive. Blocking this survival pathway can promote programmed cell death, known as apoptosis, in susceptible malignant cells.

The medicine is therefore used as a targeted therapy rather than as a general-purpose cancer medicine. The exact treatment combination, duration, and dosing schedule depend on the specific blood cancer and the prescribing specialist's treatment plan.

Active Ingredient: Venetoclax

Strength: 100 mg

Dosage Form: Film-coated tablet

Therapeutic Class: Antineoplastic Agent – BCL-2 Inhibitor

Composition: Each tablet contains Venetoclax 100 mg as the active pharmaceutical ingredient. The tablet also contains inactive excipients used to provide the appropriate tablet structure, stability, appearance, and coating.

Note: The complete list of inactive ingredients may vary by manufacturer and formulation. For a precise excipient list, refer to the product packaging or official prescribing information for the specific product.

Venetoclax dosing is highly regimen-dependent and should be taken only according to the prescription of an experienced healthcare professional. The dose is commonly introduced gradually in certain treatment settings to reduce the risk of tumor lysis syndrome.

Standard Adult Dosing

For CLL/SLL, venetoclax is generally started with a 5-week dose ramp-up schedule:

• Week 1: 20 mg once daily
• Week 2: 50 mg once daily
• Week 3: 100 mg once daily
• Week 4: 200 mg once daily
• Week 5 and thereafter: 400 mg once daily, when prescribed as the maintenance dose

For AML, the dosing schedule differs and is normally used together with another anticancer medicine such as azacitidine or decitabine. The initial dose and subsequent daily dose are determined by the prescribed combination regimen.

How to Take Venetoclax

• Take the tablet exactly as prescribed.
• Swallow the tablet whole with water.
• Do not crush, chew, or break the tablet unless specifically instructed by a healthcare professional.
• Take it with a meal and water when directed by the prescribing information.
• Maintain adequate hydration during dose initiation or escalation when your healthcare team recommends it.
• Do not change the dose or stop treatment without consulting your doctor.

Missed Dose

If a dose is missed and you remember within a relatively short period, follow the instructions provided by your healthcare professional or product information. Do not double the next dose. If vomiting occurs after taking a dose, do not automatically take another tablet; contact your healthcare team for advice.

Important Administration Precautions

Venetoclax can interact with several medicines, particularly certain CYP3A inhibitors, and dose adjustments may be necessary. Grapefruit, grapefruit products, Seville oranges, and starfruit may also interact with venetoclax and should generally be avoided unless your healthcare professional specifically advises otherwise.

Because rapid destruction of cancer cells can cause tumor lysis syndrome (TLS), appropriate preventive measures and laboratory monitoring may be required during treatment initiation and dose escalation.